Phase 2
Completed N=61
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Source: ClinicalTrials.gov NCT00088621 ↗Enrolled (actual)
61
Serious AEs
20.3%
Results posted
May 2011
Primary outcomePrimary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants
Summary
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study |
59 | — |
Eligibility Criteria
- Patients must have participated in study D1050196 (A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia) and either:
- Successfully completed
- OR
- Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy
Data sourced from ClinicalTrials.gov (NCT00088621). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.